Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Lichen Planopilaris
NCT06091956Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deucravacitinib in lichen planopilaris (LPP), sponsored by Mayo Clinic. Primary endpoint: Lichen Planopilaris Activity Index at 24 weeks. Started Nov 2023; status: completed.
02
Drugs
deucravacitinib
03
Conditions
lichen planopilaris (LPP)
Beyond the preview
Go deeper on NCT06091956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091956.